MedTrace Logo

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

NCT01217918 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-02-15

No results posted yet for this study

Summary

Study A6631027 will evaluate the safety, tolerability and pharmacokinetics of PH-797804 when administered to healthy Japanese subjects once a day (QD) for 10 days.

Conditions

  • Healthy

Interventions

DRUG

1 mg

1 mg or placebo a material sparing tablet per day for 10 days

DRUG

5 mg

5 mg or placebo as material sparing tablet per day for 10 days

DRUG

10 mg

10 mg or placebo as a material sparing tablet per day for 10 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01217918 on ClinicalTrials.gov